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Background
Depression is a leading cause of disability, with older people
particularly susceptible to poor outcomes.
Aims
To investigate whether the prevalence of depression and anti-
depressant use have changed across two decades in older
people.
Method
The Cognitive Function and Ageing Studies (CFAS I and CFAS II)
are two English population-based cohort studies of older people
aged ≥65 years, with baseline measurements for each cohort
conducted two decades apart (between 1990 and 1993 and
between 2008 and 2011). Depression was assessed by the
Geriatric Mental State examination and diagnosed with the
Automated Geriatric Examination for Computer-Assisted
Taxonomy algorithm.
Results
In CFAS I, 7635 people aged ≥65 years were interviewed, of
whom1457were diagnostically assessed. In CFAS II, 7762 people
were interviewed and diagnostically assessed. Age-standardised
depression prevalence in CFAS II was 6.8% (95% CI 6.3–7.5%),
representing a non-significant decline fromCFAS I (risk ratio 0.82,
95% CI 0.64–1.07, P = 0.14). At the time of CFAS II, 10.7% of the
population (95% CI 10.0–11.5%) were taking antidepressant
medication, more than twice that of CFAS I (risk ratio 2.79, 95% CI
1.96–3.97, P < 0.0001). Among care home residents,
depression prevalence was unchanged, but the use of
antidepressants increased from 7.4% (95% CI 3.8–13.8%) to
29.2% (95% CI 22.6–36.7%).
Conclusions
A substantial increase in the proportion of the population
reporting taking antidepressant medication is seen across two
decades for people aged ≥65 years. However there was no evi-
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Depression is a leading cause of disability worldwide and a key con-
tributor to the global burden of disease for all ages.1 Older people
may be less likely to report symptoms of depression and the pres-
ence of comorbid conditions may make depression more difficult
to diagnose.2 Estimates of prevalence of major depression in those
aged ≥75 years range from 4.6 to 9.3%,3 but sampling and measure-
ment differences in these population-based studies make it difficult
to determine whether these differences are real or artefactual.
Evidence from studies across all age groups suggest that prevalence
of major depressive disorder declines in later life,4,5 although the
reverse may be the case for the presence of clinically significant
depressive symptoms.6 Since the introduction of selective serotonin
reuptake inhibitors in the late 1980s, there has been an increase in
antidepressant prescriptions issued.7 Prescriptions dispensed for
antidepressants increased more than threefold in England
between 1991 and 2009,8 reflecting a trend observed in other
Western countries.9,10 Establishing whether there are temporal
changes in prevalence of depression among older people is a
major challenge, requiring large studies undertaken at two or
more points with sufficient time lapse, using the same sampling
methods, geographical areas, interviewing approaches and diagnos-
tic criteria. Against a backdrop of greater life expectancy and
improved health in later life, the Cognitive Function and Ageing
Studies (CFAS I and CFAS II (http://www.cfas.ac.uk)) provide a
unique opportunity to test whether the prevalence of depression
in England among people aged ≥65 years has changed over two
decades, between 1991 and 2011.
Method
The CFAS I and CFAS II are population-based cohort studies
designed to assess the changing health of older people across genera-
tions. The originalMedical ResearchCouncil CFAS (CFAS I) included
six geographical areas in England andWales, three of which were con-
tinued into CFAS II: Cambridgeshire, Newcastle and Nottingham.
Baseline interviews for CFAS I and CFAS II were conducted
between 1990 and 1993 and between 2008 and 2011, respectively.
The study design, methods and interview schedule of the two
cohort studies were identical, with the exception of a two-stage sam-
pling process used in CFAS I and a one-stage sampling used in
CFAS II. In CFAS I, individuals underwent a screening interview
(first stage) and then a subset of the screening sample were
invited to take part in a further assessment interview (second
stage). In CFAS II, screening and assessment were undertaken sim-
ultaneously during one interview for the entire sample.
Eligible participants at each centre were those aged ≥65 years
and registered with a general practice within the boundaries of
the geographical area. Those living in care homes as well as those
living independently in their own homes were included.
Participants were sampled from lists from the UK system for
primary care registration. In both CFAS I and CFAS II, stratified
random sampling was used to secure 2500 participants in each
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geographical area, with equal proportions aged 65–74 years and
aged ≥75 years. Participants were initially approached via a letter
from their registered general practice. This was followed by a visit
from a study interviewer, who undertook the interview if the indi-
vidual provided written informed consent. For individuals consid-
ered not to have mental capacity, as defined by the UK Mental
Capacity Act, a request was made to interview an informant, typic-
ally a close relative.
The interviews were conducted face to face, by a trained study
interviewer in the usual place of residence of the participant.
The interviewer captured participant responses on a laptop
computer. In CFAS I, baseline (screening) interviews contained
questions about sociodemographic characteristics, perceived
health, activities of daily living and use of health and social care ser-
vices. Participants (and/or their informant) were asked about all
medications they were currently being prescribed by their doctor
as well as over-the-counter medications and supplements.
Drug name, dose and frequency were recorded for all medications.
At the assessment interview the Geriatric Mental State examination
was undertaken. This is a standardised interview for ascertainment
of the presence or absence of mental health disorders in older age.
In CFAS II, one interview was conducted, which contained both
the screening and assessment components. Further details of the
approach and interview content have been previously published.11,12
CFAS I and CFAS II used the same Automated Geriatric
Examination for Computer-Assisted Taxonomy algorithmic
(AGECAT) approach13 to diagnose dementia, depression and
other mental health disorders among participants in the two
cohort studies. The presence or absence of depressive symptoms
are used to categorise individuals into six levels of depression sever-
ity, which can then be collapsed into three groups: no symptoms
(level d0), subclinical depression (levels d1 and d2) and case-level
depression (levels d3–d5). Subclinical depression is characterised
by minor mood symptoms and some non-specific symptoms (e.g.
loss of energy, interest or enjoyment). Case-level depression com-
prises neurotic and psychotic subtypes, with attempts of suicide
taking the diagnostic level to d4 or above. For those with more
than one diagnosis, the AGECAT algorithm determines a primary
diagnosis. Analysis presented here is restricted to those with a
primary diagnosis of case-level depression (neurotic or psychotic).
Patients were considered to be receiving antidepressants if they
reported use of medications categorised within the British
National Formulary (antidepressant sections 4.3.1–4.3.4).14
Analysis
All analyses were undertaken using weights, to adjust for (i) over-
sampling of those aged ≥75 years and (ii) non-response using
age, gender and deprivation status based on Townsend deprivation
scores15 linked to postcode (CFAS I and II). Weights also adjusted
for selection for assessment interview (CFAS I only). To account for
changes in population structures, prevalence estimates from both
CFAS I and CFAS II were calculated by standardising to the 2011
UK population age and gender distribution.
To investigate whether sociodemographic factors (age, gender,
care home residence, centre, Townsend deprivation quartile) were
associated with study diagnosis of case-level depression or being
prescribed antidepressant medication, we used binomial regression
models with a log link for each cohort to estimate risk ratios
adjusted for each of the other sociodemographic factors. To test
for a cohort effect, we used the same covariates for both cohorts
combined. We additionally included interaction terms between
each sociodemographic variable and cohort to estimate whether
the relationship between sociodemographics and depression diag-
nosis or antidepressant had changed between the two cohorts.
Ethics approval
The authors assert that all procedures contributing to this work
comply with the ethical standards of the relevant national and institu-
tional committees on human experimentation and with the Helsinki
Declaration of 1975, as revised in 2008. All procedures involving
human subjects/patients were approved by local and multi-centre
ethics committees (CFAS I: MREC99/5/22. 05/MRE05/37; CFAS II:
07/MRE05/48).
Data availability
The data sets analysed during this study are available upon reason-
able request from the CFAS team (http://www.cfas.ac.uk/cfas-i/
data/).
Results
In CFAS I, 9345 individuals were eligible and approached to take
part in the baseline screening interview in Cambridgeshire,
Newcastle and Nottingham, of whom 7635 participated (response
81.7%) and 1457 undertook the assessment interview. In CFAS II,
of the 14 228 individuals eligible to take part and approached,
7762 (54.6%) were interviewed. Details of the change in response
between the two cohorts have been previously reported.11
Supplementary Table 1 (available at https://doi.org/10.1192/bjp.
2019.193) describes the samples from each cohort and the
numbers included in analyses.
The estimated prevalence of depression among people aged≥65
years in CFAS I was 7.9% (95% CI 6.3–9.9%) and 6.8% (95% CI 6.3–
7.5%) in CFAS II (Table 1), a non-significant decline of around 20%
in prevalence in the intervening two decades (adjusted risk ratio
CFAS II versus CFAS I 0.82, 95% CI 0.64–1.07, P = 0.14). The preva-
lence of depression was higher among women than men at both
time points. There was no evidence of changes in the pattern of
prevalence across age groups. The proportion of people aged ≥65
years living in care homes has declined over the period between
the two studies,12 but prevalence of depression in care home settings
was unchanged, with approximately one in ten residents having
case-level depression (CFAS I: 10.0%, 95% CI 6.1–16.1%; CFAS II:
9.8%, 95% CI 5.9–15.8%).
Within the three centres, individuals living in Newcastle
were more likely to have case-level depression in CFAS I but
less likely to be depressed in CFAS II (risk ratio Newcastle versus
Cambridgeshire CFAS I: 3.21, 95% CI 1.56–6.59, P = 0.002;
CFAS II 0.74, 95% CI 0.58–0.94, P = 0.027; test for interaction,
P = 0.0001) (Table 2). Case-level depression was associated with
living in a more deprived area in both studies. In CFAS I, the risk
of depression was raised in all quartiles compared with the least
deprived quartile (P = 0.018). In CFAS II, higher risk was observed
in the most deprived quartile only (P = 0.0002).
The proportion of older people receiving antidepressant medi-
cation in CFAS II was more than double that in CFAS I (adjusted
risk ratio 2.79, 95% CI 1.96–3.97, P < 0.0001). Estimated prevalence
of antidepressant use from the CFAS I cohort was 4.2% (95%CI 2.9–
6.1%) and 10.7% (95% CI 10.0–11.5%) among CFAS II participants
(Table 1). In CFAS II, after adjustment for other sociodemo-
graphics, women were more likely to be receiving antidepressant
medication compared with men (risk ratio 2.05, 95% CI 1.76–
2.39, P < 0.0001) (Table 3). There was no evidence that the relation-
ship between gender and receiving antidepressant medication had
changed since CFAS I (test for interaction, P = 0.78). As with the
prevalence of case-level depression, there was no discernible age
effect on antidepressant medication prescription. In care homes the
use of antidepressants was nearly four times higher in CFAS II
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(29.2%, 95% CI 22.6–36.7%) than CFAS I (7.4%, 95% CI 3.8–
13.8%). However, after adjustment for sociodemographic factors,
the increased risk of receiving antidepressants for care home resi-
dence was similar to that of older people living in their own
homes (CFAS I: risk ratio 3.07, 95% CI 1.47–6.42, P = 0.0029;
CFAS II: risk ratio 2.76, 95% CI 2.12–3.61, P < 0.0001; test for inter-
action, P = 0.79), an indication of the change in the care home
population.
There was relatively little overlap between those who were
receiving antidepressant medications and those reaching case-
level diagnosis of depression at time of interview in either CFAS I
or in CFAS II (Fig. 1, Supplementary Table 2). In CFAS I, 1.3%
had study diagnostic-level depression and were receiving antide-
pressants, over 1 in 20 (6.8%) met study diagnostic level of depres-
sion but were not receiving antidepressants and a further 2.7% were
receiving antidepressant medication but did not meet study diagno-
sis of depression. The equivalent proportions in CFAS II were 1.9%,
4.7% and 8.8%, respectively. In both cohorts, most people with case-
level depression were not receiving antidepressant treatment and
most of those receiving antidepressants did not have a study diagno-
sis of depression at time of interview.
Discussion
From CFAS II we estimate that the prevalence of case-level depres-
sion is 6.8% in people aged ≥65 years. This was a relative but not
statistically significant decrease of around 20% since CFAS I, con-
ducted two decades earlier, after allowing for changes in age struc-
ture and other demographic differences. There was a threefold
increase in antidepressant use over the same time period. Among
CFAS I and CFAS II participants, only a minority of those with
case-level depression were receiving antidepressant medications,
and in both studies, most of those taking antidepressants did not
have depression, with this proportion of the population increasing
dramatically in CFAS II.
Strengths and limitations
The analysis presented here is based on samples drawn from popu-
lation-representative primary care registers that include residents of
care homes, use diagnostic criteria held constant between two time
points and are of sufficient scale to estimate prevalence. The
approach that we used, direct interview by rigorously trained
Table 1 Number with known depression status, depression prevalence and antidepressant treatment, by age, gender and residential status









medication, % (95% CI)
All 1457 8.1 (6.4–10.1) 4.0 (2.8–5.6) 7723 6.7 (6.1–7.3) 10.7 (10.0–11.4)
Men 531 6.3 (4.2–9.4) 2.9 (1.5–5.4) 3525 4.5 (3.9–5.3) 6.6 (5.8–7.5)
Women 926 9.1 (6.9–12.0) 4.6 (3.0–6.9) 4198 8.3 (7.5–9.2) 13.9 (12.8–15.1)
65–74 years 630 7.1 (5.2–9.7) 4.5 (2.8–7.2) 3812 6.6 (5.8–7.4) 9.8 (8.9–10.9)
75–84 years 554 8.6 (5.9–12.4) 3.7 (2.0–6.7) 2900 7.0 (6.1–8.0) 11.4 (10.2–12.6)
≥85 years 273 9.5 (5.2–16.7) 3.0 (1.5–5.9) 1011 6.1 (4.7–7.8) 11.6 (9.7–13.8)
Men in community
65–74 years 274 4.8 (2.8–8.2) 2.8 (1.2–6.6) 1859 4.3 (3.5–5.4) 6.2 (5.1–7.4)
75–84 years 166 8.5 (4.1–16.7) 3.2 (1.0–9.2) 1275 4.5 (3.4–5.8) 6.1 (4.9–7.5)
≥85 years 40 4.6 (1.3–15.3) 0 337 4.9 (3.1–7.8) 7.9 (5.3–11.5)
Overall 480 6.1 (3.9–9.4) 2.8 (1.4–5.4) 3471 4.5 (3.8–5.2) 6.3 (5.5–7.2)
Men in care homes
65–74 years 17 4.4 (0.6–27.1) 5.8 (0.7–33.3) 11 18.8 (4.4–54.1) 3.9 (0.5–25.4)
75–84 years 14 15.7 (3.8–47.0) 5.2 (0.6–33.9) 24 7.2 (1.0–38.3) 34.0 (16.5–57.2)
≥85 years 18 13.4 (3.0–43.8) 9.0 (1.2–44.8) 19 0 19.3 (6.6–44.7)
Overall 49 11.9 (4.8–26.6) 6.6 (1.9–20.5) 54 7.2 (2.2–21.0) 21.3 (11.9–35.1)
Women in community
65–74 years 329 9.0 (6.0–13.4) 5.9 (3.2–10.5) 1935 8.6 (7.4–10.0) 13.0 (11.5–14.6)
75–84 years 318 8.5 (5.2–13.5) 3.6 (1.6–8.1) 1563 8.5 (7.2–10.0) 14.4 (12.7–16.3)
≥85 years 142 11.9 (5.5–23.7) 2.6 (1.0–6.4) 562 6.6 (4.8–9.1) 10.5 (8.3–13.3)
Overall 789 9.1 (6.8–12.2) 4.4 (2.8–6.9) 4060 8.2 (7.4–9.1) 13.1 (12.1–14.2)
Women in care homes
65–74 years 9 39.8 (13.7–73.3) 10.3 (1.4–48.6) 7 0 69.3 (29.2–92.5)
75–84 years 55 10.2 (3.5–26.5) 9.6 (3.2–25.7) 38 21.0 (9.8–39.6) 38.6 (23.8–55.9)
≥85 years 70 6.0 (2.4–14.4) 6.1 (1.8–19.1) 93 7.9 (3.5–17.1) 26.6 (18.0–37.5)
Overall 134 9.4 (5.1–16.7) 7.6 (3.5–15.9) 138 10.7 (6.0–18.2) 31.9 (23.9–41.1)
Total in community
65–74 years 603 7.0 (5.0–9.6) 4.4 (2.7–7.2) 3794 6.6 (5.8–7.4) 9.7 (8.8–10.7)
75–84 years 484 8.5 (5.7–12.5) 3.5 (1.8–6.7) 2838 6.7 (5.9–7.7) 10.8 (9.6–12.0)
≥85 years 182 10.2 (5.0–19.6) 2.0 (0.8–5.0) 899 6.0 (4.6–7.8) 9.6 (7.8–11.7)
Overall 1269 8.0 (6.2–10.1) 3.8 (2.6–5.5) 7531 6.5 (6.0–7.1) 10.1 (9.4–10.8)
Total in care homes
65–74 years 26 17.7 (6.6–39.6) 7.5 (1.8–25.8) 18 11.3 (2.7–37.1) 30.3 (11.0–60.3)
75–84 years 69 11.7 (5.2–24.3) 8.5 (3.1–21.0) 62 16.2 (7.9–30.2) 37.0 (25.1–50.7)
≥85 years 88 7.2 (3.3–15.0) 6.6 (2.2–17.5) 112 6.7 (2.9–14.6) 25.5 (17.7–35.2)
Overall 183 10.0 (6.1–16.1) 7.4 (3.8–13.8) 192 9.8 (5.9–15.8) 29.2 (22.6–36.7)
By gender, standardised to 2011 age structure
Men 5.9 (3.9–8.8) 3.1 (1.6–5.9) 4.5 (3.8–5.3) 6.4 (5.9–7.3)
Women 9.1 (6.9–11.9) 4.9 (3.1–7.6) 8.5 (7.7–9.5) 13.8 (12.7–15.0)
Total 7.9 (6.3–9.9) 4.2 (2.9–6.1) 6.8 (6.3–7.5) 10.7 (10.0–11.5)
CFAS, Cognitive Function and Ageing Studies.
a. Residential status missing for five individuals in CFAS I.
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interviewers across sites, with standardised detailed questioning by
validated methods, should ensure that our detection of depression is
comparable across time. In drawing conclusions from our findings,
the methodological limitations need to be considered. In spite of
identical recruitment approaches, non-response in CFAS II was
greater than in that achieved in CFAS I two decades earlier.
However, the risk to biased estimates owing to lack of representa-
tiveness is limited by back-weighting of factors associated with
non-response. Our measures of medication are based on what is
reported as taken rather than what is prescribed, and it is not pos-
sible to determine the appropriateness or otherwise of antidepres-
sant prescribing for study participants. Among older people, the
level of non-adherence to medication16 presents challenges for
studies based on prescription data.
The two-stage design (screening and assessment) of CFAS I
limits the number of participants with diagnostic assessment,
meaning the power to detect associations was greater at CFAS II.
The analyses we report here are cross-sectional for each cohort,
which limits our ability to comment on changes in duration of
depressive or treatment episode. Both in the UK17 and elsewhere,18
psychological therapies are more widely used than at the time of
CFAS I, but we did not ask participants about this directly and so
cannot include non-medication treatment in our analysis.
Findings in the context of the literature
CFAS I andCFAS II have allowed for direct comparison of changes in
prevalence and treatment of depression among people aged≥65 years
across two decades. Prevalence estimates of depression are higher if
samples are drawn from primary care attenders19 or where measure-
ment is restricted to symptom scales.20 Our estimated prevalence of
late-life depression from CFAS II is consistent with two reviews of
epidemiological studies of comparable age groups. In the first,
Table 2 Adjusteda risk ratios for sociodemographic factors and depression, CFAS I and CFAS II
CFAS I risk
ratio (95% CI) P-value
CFAS II risk
ratio (95% CI) P-value
Test for interaction
(CFAS I and CFAS II) P-value
Gender
Male Ref 0.40 Ref <0.0001 0.16
Female 1.25 (0.74–2.11) 1.87 (1.55–2.26)
Age group
65–74 years Ref 0.78 Ref 0.23 0.44
75–84 years 1.06 (0.64–1.76) 1.02 (0.85–1.26)
≥85 years 1.30 (0.62–2.72) 0.79 (0.59–1.06)
Residence
Community Ref 0.74 Ref 0.12 0.47
Care home 1.12 (0.59–2.13) 1.51 (0.89–2.57)
Centre
Cambridgeshire Ref 0.0022 Ref 0.027 0.0001
Newcastle 3.21 (1.56–6.59) 0.74 (0.58–0.94)
Nottingham 1.80 (0.84–3.84) 0.94 (0.76–1.17)
Townsend deprivation index (quartiles)
Q1 (least deprived) Ref 0.018 Ref 0.0002 0.0096
Q2 2.18 (1.06–4.49) 0.89 (0.69–1.13)
Q3 3.07 (1.51–6.25) 1.04 (0.82–1.33)
Q4 (most deprived) 2.27 (1.08–4.75) 1.56 (1.22–2.00)
CFAS, Cognitive Function and Ageing Studies; Ref, reference value; Q, quartile.
a. Risk ratios adjusted for all other covariates.
Table 3 Adjusteda risk ratios for sociodemographic factors and antidepressant treatment, CFAS I and CFAS II
CFAS I risk
ratio (95% CI) P-value
CFAS II risk
ratio (95% CI) P-value
Test for interaction (CFAS I
and CFAS II) P-value
Gender
Male Ref 0.15 Ref <0.0001 0.78
Female 1.83 (0.81–4.11) 2.05 (1.76–2.39)
Age group
65–74 years Ref 0.24 Ref 0.047 0.46
75–84 years 0.76 (0.34–1.69) 1.08 (0.93–1.25)
≥85 years 0.47 (0.19–1.13) 0.82 (0.65–1.02)
Residence
Community Ref 0.0029 Ref <0.0001 0.79
Care home 3.07 (1.47–6.42) 2.76 (2.12–3.61)
Centre
Cambridgeshire Ref 0.34 Ref <0.0001 0.93
Newcastle 0.93 (0.37–2.36) 1.01 (0.84–1.20)
Nottingham 0.58 (0.24–1.36) 0.68 (0.56–0.82)
Townsend deprivation index (quartiles)
Q1 (least deprived) Ref 0.13 Ref 0.029 0.10
Q2 2.23 (0.87–5.75) 0.86 (0.71–1.05)
Q3 0.85 (0.33–2.17) 0.95 (0.78–1.14)
Q4 (most deprived) 1.60 (0.57–4.49) 1.19 (0.98–1.44)
CFAS, Cognitive Function and Ageing Studies; Ref, reference value; Q, quartile.
a. Risk ratios adjusted for all other covariates.
Arthur et al
4
estimates of major depression according to ICD-10 or DSM-IV cri-
teria ranged from 0.9 to 9.4%, with variation likely owing to themeth-
odological and contextual differences of the reviewed studies.21 In the
second, pooled prevalence from 13 studies was 7.2%.3
Prevalence of case-level depression decreased from 7.9% in
CFAS I to 6.8% in CFAS II, but after adjustment this change was
not statistically significant. Although other studies have looked at
depression across time with the same methodology,22–24 their
focus has been on younger age groups, making direct comparison
difficult. A relatively short-term comparison from a repeat popula-
tion interview survey between 1998 and 2004 of Australian adults of
all ages found no change in prevalence of depression.25 Analyses of
general practice attenders, where prevalence estimates will be higher
than those from population studies, found that the incidence
decreased from 22.5 to 14.0 per 1000 person-years between 1996
and 2006, and this decline was greater among those aged ≥65
years.26 In our analysis there was evidence of a change over time
in the association between depression and living in a deprived
area. That the risk appears to be confined to those in the most
deprived quartile is perhaps indicative of changing social structures
in England, with a decreasing proportion of the population being
socioeconomically classified as ‘working class’.27
Taking antidepressant medication increased from 4.0 to 10.7%
over the 20-year period. This is similar to the rise reported by
others over a similar time period.8–10 Depression can be effectively
treated by medication; therefore it is expected that there will be a
substantial proportion of people taking medication, but not report-
ing the symptoms of depression. In CFAS I the number of those
with untreated case-level depression was over twice that of those
receiving antidepressant medication without a diagnosis. These pro-
portions were reversed in CFAS II. There are a number of possible
explanations for this apparent mismatch between prevalence and
treatment, although the observational study design precludes any
inference of a causal relationship. For those untreated, we cannot
say if this is because of treatment not being offered, not being
accepted, having been unsuccessful in the past or whether other,
non-pharmacological treatments were being received. Participants
who were not identified as depressed but were receiving antidepres-
sant medications may have been treated successfully in the past and
continue to take medications, perhaps preventing a rise in depres-
sion prevalence that might have been observed otherwise.
Antidepressants may be more likely to be used to treat depression
that does not reach the case-level threshold used in this study.
Authors from other epidemiological studies have suggested that
the need for treatment is poorly matched with provision.28
It is unclear whether observed increases in treatment are a
reflection of overdiagnosis, better recognition and prescribing, or
the prescribing of antidepressant medication for conditions other
than depression. The comparisons made here were during a time
of change in the way depression is detected and treated. In
England, where most older people with depression are managed
in primary care settings, policy shifts have been toward greater sur-
veillance of those with chronic diseases. Depression directly affects
1 in 15 people aged ≥65 years, with its effects felt by families and
friends. Over two decades, substantial increases in access to anti-
depressant medication do not appear to be associated with change
in prevalence of late-life depression. The natural history of treated
and untreated depression, particularly for older people, remains
poorly understood.
Antony Arthur , PhD, Professor of Nursing Science, School of Health Sciences,
University of East Anglia, UK; George M. Savva, PhD, Statistician, Core Science
Resources, Quadram Institute Biosciences, UK; Linda E. Barnes, RGN, CFAS National
Co-ordinator, Department of Public Health and Primary Care, University of Cambridge,
UK; Ayda Borjian-Boroojeny, Medical Student, Norwich Medical School, University of
East Anglia, UK; Tom Dening, MD, Professor of Dementia Research, School of Medicine,
University of Nottingham, UK; Carol Jagger, PhD, Professor of Epidemiology and Ageing,
Institute for Health and Society, Newcastle University, UK; Fiona E. Matthews , PhD,
Professor of Epidemiology, Newcastle University; and University of Cambridge, UK;
Louise Robinson, MD, Professor of Primary Care and Ageing, Institute for Health and
Society, Newcastle University, UK; Carol Brayne, MD, Professor of Public Health
Medicine, Department of Public Health and Primary Care, University of Cambridge, UK;
and the Cognitive Function and Ageing Studies Collaboration, see
Acknowledgements
Correspondence: Antony Arthur, School of Health Sciences, University of East Anglia,
Norwich Research Park, Norwich NR4 7TJ, UK. Email: antony.arthur@uea.ac.uk
First received 30 Oct 2018, final revision 2 Jul 2019, accepted 30 Jul 2019
Supplementary material
Supplementary material is available online at https://doi.org/10.1192/bjp.2019.193.
Funding
CFAS I was funded by the Medical Research Council (research grant G9901400) and the UK
Department of Health. CFAS II was funded by the Medical Research Council (research grant
G0601022) and the Alzheimer’s Society (grant 294); additional support was provided from the
National Institute for Health Research’s Clinical Research Network in West Anglia and Trent,
and the Dementias and Neurodegenerative Disease Research Network in Newcastle.
Acknowledgements
We thank participants, their families, general practitioners and their staff, and primary care







CFAS II CFAS IICFAS I
Men























Fig. 1 Prevalence of depression and antidepressant treatment by gender, CFAS I and CFAS II.
CFAS, Cognitive Function and Ageing Studies.
Changing depression prevalence and treatment among older people
5
Cambridge, Nottingham and Newcastle (UK), and the CFAS core data management team at
Cambridge.
Members of the CFAS Cambridge core team and fieldwork support: E. Green, L. Gao and
R. Barnes. CFAS management committee members: A. Arthur, C. Baldwin, L.E. Barnes,
C. Brayne, A. Comas-Herrera, T. Dening, G. Forster, S. Harrison, P.G. Ince, C. Jagger, F.E.
Matthews, I.G. McKeith, B. Parry, J. Pickett, L. Robinson, B.C.M. Stephan, S. Wharton,
R. Wittenberg and B. Woods. CFAS biological resource advisory committee members:
R. Weller (Chair).
References
1 World Health Organization (WHO). Depression. WHO, 2017 (http://www.who.
int/mediacentre/factsheets/fs369/en/).
2 Wetherell JL, Petkus AJ, McChesney K, Stein MB, Judd PH, Rockwell E, et al.
Older adults are less accurate than younger adults at identifying symptoms of
anxiety and depression. J Nerv Ment Dis 2009; 197(8): 623–6.
3 Luppa M, Sikorski C, Luck T, Ehreke L, Konnopka A, Wiese B, et al. Age- and
gender-specific prevalence of depression in latest-life: systematic review and
meta-analysis. J Affect Disord 2012; 136(3): 212–21.
4 Mojtabai R, Olfson M. Major depression in community-dwelling middle-aged
and older adults: prevalence and 2- and 4-year follow-up symptoms. Psychol
Med 2004; 34(4): 623–34.
5 Scott KM, Von Korff M, Alonso J, Angermeyer M, Bromet EJ, Bruffaerts R, et al.
Age patterns in the prevalence of DSM-IV depressive/anxiety disorders with
and without physical co-morbidity. Psychol Med 2008; 38(11): 1659–69.
6 Snowdon J, Draper B, Brodaty H, Ames D, Chiu E. Prevalence and treatment of
late life depression. Aust N Z J Psychiatry 2010; 44(11): 1054.
7 Hillhouse TM, Porter JH. A brief history of the development of antidepressant
drugs: frommonoamines to glutamate. Exp Clin Psychopharmacol 2015; 23(1):
1–21.




9 Olfson M, Marcus SC. National patterns in antidepressant medication treat-
ment. Arch Gen Psychiatry 2009; 66(8): 848–56.
10 Aarts N, Noordam R, Hofman A, Tiemeier H, Stricker BH, Visser LE. Utilization
patterns of antidepressants between 1991 and 2011 in a population-based
cohort of middle-aged and elderly. Eur Psychiatry 2014; 29(6): 365–70.
11 Gao L, Green E, Barnes LE, Brayne C, Matthews FE, Robinson L, et al. Changing
non-participation in epidemiological studies of older people: evidence from the
Cognitive Function and Ageing Study I and II. Age Ageing 2015; 44(5): 867–73.
12 Matthews FE, Arthur A, Barnes LE, Bond J, Jagger C, Robinson L, et al. A two-
decade comparison of prevalence of dementia in individuals aged 65 years and
older from three geographical areas of England: results of the Cognitive
Function and Ageing Study I and II. Lancet 2013; 382(9902): 1405–12.
13 Copeland JR, Dewey ME, Griffiths-Jones HM. A computerized psychiatric
diagnostic system and case nomenclature for elderly subjects: GMS and
AGECAT. Psychol Med 1986; 16(1): 89–99.
14 British Medical Association & Royal Pharmaceutical Society of Great Britain.
British National Formulary (March 2015, Issue 69). BMJ Books and
Pharmaceutical Press, 2015.
15 Townsend P, Phillimore P, Beattie A.Health and Deprivation: Inequality and the
North. Croom Helm, 1988.
16 Zelko E, Klemenc-Ketis Z, Tusek-Bunc K. Medication adherence in elderly with
polypharmacy living at home: a systematic review of existing studies. Mater
Sociomed 2016; 28(2): 129–32.
17 Health and Social Care Information Centre. Psychological Therapies, England:
Annual Report on the Use of Improving Access to Psychological Therapies
Services – 2012–13. Health and Social Care Information Centre, part of the
Government Statistical Service, 2014 (https://files.digital.nhs.uk/publicatio-
nimport/pub13xxx/pub13339/psyc-ther-ann-rep-2012-13.pdf).
18 Goldney RD, Fisher LJ, Grande ED, Taylor AW, Hawthorne G. Have education
and publicity about depressionmade a difference? Comparison of prevalence,
service use and excess costs in South Australia: 1998 and 2004. Aust N Z J
Psychiatry 2007; 41(1): 38–53.
19 Licht-Strunk E, van der Kooij KG, van Schaik DJ, van Marwijk HW, van Hout HP,
de Haan M, et al. Prevalence of depression in older patients consulting their
general practitioner in The Netherlands. Int J Geriatr Psychiatry 2005; 20(11):
1013–9.
20 Solhaug HI, Romuld EB, Romild U, Stordal E. Increased prevalence of depres-
sion in cohorts of the elderly: an 11-year follow-up in the general population -
the HUNT study. Int Psychogeriatr 2012; 24(1): 151–8.
21 Djernes JK. Prevalence and predictors of depression in populations of elderly: a
review. Acta Psychiatr Scand 2006; 113(5): 372–87.
22 de Graaf R, ten Have M, van Gool C, van Dorsselaer S. Prevalence of mental
disorders and trends from 1996 to 2009. Results from the Netherlands Mental
Health Survey and Incidence Study-2. Soc Psychiatry Psychiatr Epidemiol 2012;
47(2): 203–13.
23 Spiers N, Brugha TS, Bebbington P, McManus S, Jenkins R, Meltzer H. Age and
birth cohort differences in depression in repeated cross-sectional surveys in
England: the National Psychiatric Morbidity Surveys, 1993 to 2007. Psychol
Med 2012; 42(10): 2047–55.
24 Jeuring HW, Comijs HC, Deeg DJH, Stek ML, HuismanM, Beekman ATF. Secular
trends in the prevalence of major and subthreshold depression among 55–64-
year olds over 20 years. Psychol Med 2018; 48(11): 1824–34.
25 Hawthorne G, Goldney R, Taylor AW. Depression prevalence: is it really
increasing? Aust N Z J Psychiatry 2008; 42(7): 606–16.
26 Rait G, Walters K, Griffin M, Buszewicz M, Petersen I, Nazareth I. Recent trends
in the incidence of recorded depression in primary care. Br J Psychiatry 2009;
195(6): 520–4.
27 Goldthorpe JH. Social class mobility in modern Britain: changing structure,
constant process. J Brit Acad 2016; 4: 89–111.
28 Mojtabai R, JormAF. Trends in psychological distress, depressive episodes and
mental health treatment-seeking in the United States: 2001–2012. J Affect
Disord 2015; 174: 556–61.
Arthur et al
6
